SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in <i>De Novo</i> Metastatic Castration-Sensitive Prostate Cancer

Abstract

In real-world settings, SPOP mutations were associated with improved outcomes to ADT plus ARAT (but not ADT plus docetaxel) in patients with dn-mCSPC. This may serve as a predictive biomarker to guide treatment selection for patients with mCSPC.